Suppr超能文献

接受分析性治疗中断的HIV感染者的影像学检查与活检

Imaging and biopsy of HIV-infected individuals undergoing analytic treatment interruption.

作者信息

Lau Chuen-Yen, Adan Matthew A, Earhart Jessica, Seamon Cassie, Nguyen Thuy, Savramis Ariana, Adams Lindsey, Zipparo Mary-Elizabeth, Madeen Erin, Huik Kristi, Grossman Zehava, Chimukangara Benjamin, Wulan Wahyu Nawang, Millo Corina, Nath Avindra, Smith Bryan R, Ortega-Villa Ana M, Proschan Michael, Wood Bradford J, Hammoud Dima A, Maldarelli Frank

机构信息

HIV Dynamics and Replication Program, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, United States.

Critical Care Medicine Department, Clinical Center (CC), National Institutes of Health (NIH), Bethesda, MD, United States.

出版信息

Front Med (Lausanne). 2022 Aug 22;9:979756. doi: 10.3389/fmed.2022.979756. eCollection 2022.

Abstract

BACKGROUND

HIV persistence during antiretroviral therapy (ART) is the principal obstacle to cure. Lymphoid tissue is a compartment for HIV, but mechanisms of persistence during ART and viral rebound when ART is interrupted are inadequately understood. Metabolic activity in lymphoid tissue of patients on long-term ART is relatively low, and increases when ART is stopped. Increases in metabolic activity can be detected by F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and may represent sites of HIV replication or immune activation in response to HIV replication.

METHODS

FDG-PET imaging will be used to identify areas of high and low metabolic uptake in lymphoid tissue of individuals undergoing long-term ART. Baseline tissue samples will be collected. Participants will then be randomized 1:1 to continue or interrupt ART analytic treatment interruption (ATI). Image-guided biopsy will be repeated 10 days after ATI initiation. After ART restart criteria are met, image-guided biopsy will be repeated once viral suppression is re-achieved. Participants who continued ART will have a second FDG-PET and biopsies 12-16 weeks after the first. Genetic characteristics of HIV populations in areas of high and low FDG uptake will be assesed. Optional assessments of non-lymphoid anatomic compartments may be performed to evaluate HIV populations in distinct anatomic compartments.

ANTICIPATED RESULTS

We anticipate that PET standardized uptake values (SUV) will correlate with HIV viral RNA in biopsies of those regions and that lymph nodes with high SUV will have more viral RNA than those with low SUV within a patient. Individuals who undergo ATI are expected to have diverse viral populations upon viral rebound in lymphoid tissue. HIV populations in tissues may initially be phylogenetically diverse after ATI, with emergence of dominant viral species (clone) over time in plasma. Dominant viral species may represent the same HIV population seen before ATI.

DISCUSSION

This study will allow us to explore utility of PET for identification of HIV infected cells and determine whether high FDG uptake respresents areas of HIV replication, immune activation or both. We will also characterize HIV infected cell populations in different anatomic locations. The protocol will represent a platform to investigate persistence and agents that may target HIV populations.

STUDY PROTOCOL REGISTRATION

Identifier: NCT05419024.

摘要

背景

抗逆转录病毒疗法(ART)期间的HIV持续存在是治愈的主要障碍。淋巴组织是HIV的一个储存库,但对于ART期间的持续存在机制以及ART中断时的病毒反弹机制,我们了解得还不够充分。长期接受ART治疗的患者,其淋巴组织中的代谢活性相对较低,而在停止ART后会增加。代谢活性的增加可以通过F-氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)检测到,这可能代表HIV复制的部位或对HIV复制产生反应的免疫激活部位。

方法

FDG-PET成像将用于识别接受长期ART治疗的个体淋巴组织中代谢摄取高和低的区域。将采集基线组织样本。然后,参与者将按1:1随机分组,继续或中断ART分析性治疗中断(ATI)。在ATI开始10天后将重复进行图像引导活检。在达到ART重新启动标准后,一旦再次实现病毒抑制,将再次进行图像引导活检。继续接受ART治疗的参与者将在第一次检查后的12至16周进行第二次FDG-PET检查和活检。将评估FDG摄取高和低区域的HIV群体的基因特征。可对非淋巴解剖区域进行可选评估,以评估不同解剖区域中的HIV群体。

预期结果

我们预计PET标准化摄取值(SUV)将与这些区域活检中的HIV病毒RNA相关,并且在同一患者中,SUV高的淋巴结比SUV低的淋巴结具有更多的病毒RNA。预计接受ATI的个体在淋巴组织病毒反弹时会有不同的病毒群体。ATI后,组织中的HIV群体最初可能在系统发育上是多样的,随着时间的推移,血浆中会出现占主导地位的病毒种类(克隆)。占主导地位的病毒种类可能代表ATI之前所见的相同HIV群体。

讨论

这项研究将使我们能够探索PET在识别HIV感染细胞方面的效用,并确定FDG摄取高是否代表HIV复制区域、免疫激活区域或两者兼有。我们还将对不同解剖位置的HIV感染细胞群体进行特征描述。该方案将成为一个研究HIV持续存在及可能靶向HIV群体的药物的平台。

研究方案注册

标识符:NCT05419024。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4971/9441850/03434bc15fa1/fmed-09-979756-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验